Share subscriptions based on the resolution by Nanoform Finland Plc’s Annual General Meeting 2026 on remuneration of the Board of Directors
Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Nanoform Finland Plc | Company Release | June 10, 2026 at 08:30:00 EEST
Helsinki, Finland – A total of 85 000 Nanoform Finland Plc’s (the “Company” or “Nanoform“) new shares has been subscribed for by the members of the Board of Directors of the Company. The shares are issued as part of remuneration of the members of the Board of Directors in accordance with the resolution by the Company’s Annual General Meeting April 21, 2026 (the “AGM”). As noted in the AGM, the share price 0,96 euros corresponds to volume-weighted average share price over ten (10) trading days following the publication of the interim report of the Company for 1 January 2026 – 31 March 2026 (the “Q1 Report”). The Q1 Report was published on May 19, 2026.
The entire subscription price of EUR 81,600 for the share subscriptions will be entered in the Company’s reserve for invested unrestricted equity. The shares subscribed for are expected to be registered in the Trade Register on or about August 2026, as of which date the new shares will establish shareholder rights and the total amount of shares in the Company will be 85,755,120. The shares will be traded on the NASDAQ Helsinki Plc’s First North Growth Market Finland marketplace together with the old shares on or about August 2026.
For further information, please contact:
Peter Hänninen, General Counsel
peter.hanninen@nanoform.com
+358 50 353 0408
For investor relations queries, please contact:
Henri von Haartman, Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 8 588 685 70, certifiedadviser@dnbcarnegie.se. For more information, please visit www.nanoform.com.